ClinicalTrials.gg
Status unknownNCT04904224PECUpdated May 27, 2021

Diagnosis of Inflammatory Bowel Disease by Examining the Entire Bowel by Pan-intestinal Capsule Endoscopy

An interventional study of Panintestinal video capsule endoscopy and Colonoscopy in Inflammatory Bowel Diseases and Morbus Crohn, sponsored by Robert Bosch Medical Center. Status unknown at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-27.

Sponsored by Robert Bosch Medical Center · Not applicable, Interventional, and Diagnostic

How we know

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 89 studies in Inflammatory Bowel Diseases with a site in Germany — 13 open to participants now, 19 under way, 4 of them phase 3. Inflammatory Bowel Diseases · Germany.

Planned enrollment
30th of 68
150 · median 140
Started
2021
with 6 others
No phase
15 of 89
4 open now
Registered
66th of 89
by date

Among the 89 studies in Inflammatory Bowel Diseases with a site in Germany, this one is the 30th largest by planned enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2021, is one of 15 with no phase, and was the 66th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

13 of the 89 studies in Inflammatory Bowel Diseases with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Inflammatory Bowel Diseases with a site in Germany, or all of them as a file.
02

Study summary

The aim of this study is to discover inflammatory changes in the gastrointestinal tract in adult patients with suspicion of a chronic inflammatory bowel disease (IBD) by examining the entire bowel, including the small intestine, by using a video capsule. The study compares the video capsule endoscopy with colonoscopy with the question of inflammation and patient satisfaction with the respective examinations.

The study is aimed at participants who present to a gastroenterologist because of their complaints like persistent abdominal pain or diarrhea. An infectious genesis and celiac disease must be ruled out in advance.

In addition, the determination of the fecal calprotectin (fCal) is necessary for this study. Fecal calprotectin is a stool marker for the severity of an inflammation of the gastrointestinal tract, an increased fecal calprotectin can be an initial indication for the presence of a chronic inflammatory bowel disease.

As mentioned above, participants will be examined in one of two ways: either with an examination of the small and large intestines using video capsule endoscopy in one examination (i.e. ,panintestinal capsule endoscopy', PICE) or a colonoscopy is performed as the standard treatment. Which of the two methods is used will be decided by lot, electronically controlled.

Colon cleansing is necessary in preparation for both examinations. The advantage of being assigned to the video capsule group is, in addition to showing the entire intestine in one examination, that no sedation is necessary for this examination.

In addition to the examination, participants have to fill out a questionnaire with information about their state of affairs, their well-being and their experience with the examination. After a period of six month the participants will be contact by phone to inquire about their current state of health.

Read the detailed description

People who contact a gastroenterologist because of persistent complaints like abdominal pain or diarrhea are suspicious having an inflammatory bowel disease and maybe meet the eligibility requirements for the study.

After checking the inclusion and exclusion criteria further necessary data (medical history, secondary diagnoses, previous examinations, etc.) as well as laboratory parameters (especially signs of inflammation and fecal calprotectin) are collected. After being informed about the study and potential risks, all patients giving written informed consent and who meet the eligibility requirements will be randomized in an open-label manner (participant and investigator) in a 1:1 ratio to video capsule endscopy intervention or colonoscopy. A follow-up by phone to evaluate the state of health is planned after six months.

The study center and established specialist practices are responsible for the study inclusion.

There will be no recruitment by advertising. Only participants who are introducing themselves due to complaints are offered study participation.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Morbus Crohn

Keywords

  • Abdominal Pain
  • Diarrhea
  • Video Capsule Endoscopy
  • Panintestinal Video Capsule Endoscopy
  • Fecal Calprotectin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Apply one of the following

    • Chronic abdominal pain for at least 4 weeks, min. 3/10 points on a visual pain scale
    • Persistent diarrhea, Stool frequency of at least 4 per day
    • doctor visit due to the mentioned complaints
  • Exclusion of an infectious genesis or coeliac disease by serological testing or duodenal , if necessary
  • Consent to study participation
  • Fecal calprotectin > 50 µg/g

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • metastasized malignoma
  • terminal renal insufficiency, renal insufficiency requiring dialysis
  • swallowing disorder
  • age \< 18 years
  • lack of consent
  • infectious genesis of symptomps
  • coeliac disease
  • Relative :

    • evidence of strictures, strictures or fistulas in the gastrointestinal tract in imaging or in high suggestive symptoms, e.g. Ileus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    PICE

    Participants receive a panintestinal video capsule endoscopy (PICE)

    Device: Panintestinal video capsule endoscopy

  • Active comparator
    Colonoscopy

    Participants receive an (Ileo-)Colonoscopy

    Device: Colonoscopy

Interventions

  • DevicePanintestinal video capsule endoscopy

    Performing a video capsule endoscopy using the Pill Cam Crohn's capsule from Medtronic

    Also known as: PillCam Crohn's Capsule

  • DeviceColonoscopy

    Performing a standard colonoscopy using the colonoscope available in the study center

    Also known as: (Ileo-)Colonoscopy

06

What researchers measure

Primary outcomes

  1. Number of Participants with Evidence of inflammatory Alterations in the Gastrointestinal Tract

    Detection of inflammatory changes using vidoe capsule endoscopy or colonoscopy

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Number of Diagnosis of a Chronic Inflammatory Bowel Disease

    Diagnosis of inflammatory bowel disease depending on the examination findings of video capsule endoscopy or colonoscopy

    Time frame: through study completion, an average of 1 year

  2. Number of Participants with Indication for a Therapy because of the Examination findings

    Indication for a surgical or drug therapy

    Time frame: through study completion, an average of 1 year

07

Study locations

6 of 6 sites recruiting
  • Praxis Gersemann
    Ditzingen, Baden-Württemberg 71254, Germany
    Recruiting
    • Michael Gersemann · Contact
  • Praxis Escher
    Leonberg, Baden-Württemberg 71229, Germany
    Recruiting
    • Markus Escher · Contact
  • Gastroenterologische Schwerpunktpraxis
    Stuttgart, Baden-Württemberg 70190, Germany
    Recruiting
    • Boris Uhel · Contact
    • Hartmut Goelkel · Contact
    • Hans-Michael Haemmerle · Sub investigator
  • Robert Bosch Medical Center
    Stuttgart, Baden-Württemberg 70376, Germany
    Recruiting
  • Gastroenterologie am Pragsattel
    Stuttgart, Baden-Württemberg 70469, Germany
    Recruiting
    • Oliver Mueller · Contact
    • Marcus Pichler · Contact
  • Ambulante Gastroenterologie
    Stuttgart, Baden-Württemberg 70565, Germany
    Recruiting
    • Karl M. Teubner · Contact
    • Dietmar Vogler · Contact
    • Albrecht G. Maier · Sub investigator
08

References and documents

Publications

  • Albert JG, Martiny F, Krummenerl A, Stock K, Lesske J, Gobel CM, Lotterer E, Nietsch HH, Behrmann C, Fleig WE. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut. 2005 Dec;54(12):1721-7. doi: 10.1136/gut.2005.069427. Epub 2005 Jul 14. PubMed 16020490 ↗
  • Albert JG, Kotsch J, Kostler W, Behl S, Kaltz B, Bokemeyer B, Dollinger MM, Haerting J, Fleig WE. Course of Crohn's disease prior to establishment of the diagnosis. Z Gastroenterol. 2008 Feb;46(2):187-92. doi: 10.1055/s-2007-963524. PubMed 18253897 ↗
  • Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, Notarbartolo A, Averna MR. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003 Jun;49(6 Pt 1):861-7. doi: 10.1373/49.6.861. PubMed 12765980 ↗
  • Cotter J, Dias de Castro F, Moreira MJ, Rosa B. Tailoring Crohn's disease treatment: the impact of small bowel capsule endoscopy. J Crohns Colitis. 2014 Dec;8(12):1610-5. doi: 10.1016/j.crohns.2014.02.018. Epub 2014 Mar 14. PubMed 24631311 ↗
  • Dionisio PM, Gurudu SR, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol. 2010 Jun;105(6):1240-8; quiz 1249. doi: 10.1038/ajg.2009.713. Epub 2009 Dec 22. PubMed 20029412 ↗
  • Fleiss JL, Tytun A, Ury HK. A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics. 1980 Jun;36(2):343-6. PubMed 26625475 ↗
  • Hale M, McAlindon ME. Capsule endoscopy as a panenteric diagnostic tool. Br J Surg. 2014 Feb;101(3):148-9. doi: 10.1002/bjs.9321. Epub 2013 Nov 19. No abstract available. PubMed 24254382 ↗
  • Hale MF, Drew K, McAlindon ME, Sidhu R. The diagnostic accuracy of faecal calprotectin and small bowel capsule endoscopy and their correlation in suspected isolated small bowel Crohn's disease. Eur J Gastroenterol Hepatol. 2016 Oct;28(10):1145-50. doi: 10.1097/MEG.0000000000000696. PubMed 27384306 ↗
  • Hale MF, Sidhu R, McAlindon ME. Capsule endoscopy: current practice and future directions. World J Gastroenterol. 2014 Jun 28;20(24):7752-9. doi: 10.3748/wjg.v20.i24.7752. PubMed 24976712 ↗
  • Jensen MD, Nathan T, Rafaelsen SR, Kjeldsen J. Diagnostic accuracy of capsule endoscopy for small bowel Crohn's disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol. 2011 Feb;9(2):124-9. doi: 10.1016/j.cgh.2010.10.019. Epub 2010 Nov 5. PubMed 21056692 ↗
  • Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol. 2011 Jun;46(6):694-700. doi: 10.3109/00365521.2011.560680. Epub 2011 Apr 1. PubMed 21456899 ↗
  • May A, Albert J, Keuchel M, Moog G, Hartmann D. [Capsule endoscopy for the diagnosis of small bowel diseases. An updated statement by the endoscopy section of DGVS]. Z Gastroenterol. 2010 Dec;48(12):1384-404. doi: 10.1055/s-0029-1245788. Epub 2010 Nov 24. No abstract available. German. PubMed 21108180 ↗
  • Pennazio M, Spada C, Eliakim R, Keuchel M, May A, Mulder CJ, Rondonotti E, Adler SN, Albert J, Baltes P, Barbaro F, Cellier C, Charton JP, Delvaux M, Despott EJ, Domagk D, Klein A, McAlindon M, Rosa B, Rowse G, Sanders DS, Saurin JC, Sidhu R, Dumonceau JM, Hassan C, Gralnek IM. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2015 Apr;47(4):352-76. doi: 10.1055/s-0034-1391855. Epub 2015 Mar 31. PubMed 25826168 ↗
  • Petruzziello C, Calabrese E, Onali S, Zuzzi S, Condino G, Ascolani M, Zorzi F, Pallone F, Biancone L. Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's disease. J Crohns Colitis. 2011 Apr;5(2):139-47. doi: 10.1016/j.crohns.2010.12.004. Epub 2011 Jan 14. PubMed 21453883 ↗
  • Smalley W, Falck-Ytter C, Carrasco-Labra A, Wani S, Lytvyn L, Falck-Ytter Y. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology. 2019 Sep;157(3):851-854. doi: 10.1053/j.gastro.2019.07.004. Epub 2019 Jul 11. No abstract available. PubMed 31302098 ↗
  • Spada C, Hassan C, Galmiche JP, Neuhaus H, Dumonceau JM, Adler S, Epstein O, Gay G, Pennazio M, Rex DK, Benamouzig R, de Franchis R, Delvaux M, Deviere J, Eliakim R, Fraser C, Hagenmuller F, Herrerias JM, Keuchel M, Macrae F, Munoz-Navas M, Ponchon T, Quintero E, Riccioni ME, Rondonotti E, Marmo R, Sung JJ, Tajiri H, Toth E, Triantafyllou K, Van Gossum A, Costamagna G; European Society of Gastrointestinal Endoscopy. Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2012 May;44(5):527-36. doi: 10.1055/s-0031-1291717. Epub 2012 Mar 2. PubMed 22389230 ↗
  • Spada C, Hassan C, Munoz-Navas M, Neuhaus H, Deviere J, Fockens P, Coron E, Gay G, Toth E, Riccioni ME, Carretero C, Charton JP, Van Gossum A, Wientjes CA, Sacher-Huvelin S, Delvaux M, Nemeth A, Petruzziello L, de Frias CP, Mayershofer R, Amininejad L, Dekker E, Galmiche JP, Frederic M, Johansson GW, Cesaro P, Costamagna G. Second-generation colon capsule endoscopy compared with colonoscopy. Gastrointest Endosc. 2011 Sep;74(3):581-589.e1. doi: 10.1016/j.gie.2011.03.1125. Epub 2011 May 20. Erratum In: Gastrointest Endosc. 2011 Nov;74(5):1174. Aminejab, Leila [corrected to Amininejad, Leila]. PubMed 21601200 ↗
  • Stange EF. Colitis ulcerosa - Morbus Crohn. UNI-MED SCIENCE, 5. Auflage, 2016
  • Wehkamp J, Gotz M, Herrlinger K, Steurer W, Stange EF. Inflammatory Bowel Disease. Dtsch Arztebl Int. 2016 Feb 5;113(5):72-82. doi: 10.3238/arztebl.2016.0072. PubMed 26900160 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Mar 2022, 12 months after the start.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2021
First posted
May 27, 2021
StartActual
Mar 7, 2021
Primary completionEst.
Mar 31, 2022
CompletionEst.
Mar 31, 2023
Last update
May 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04904224
Lead sponsor
Robert Bosch Medical Center
Collaborators
Medtronic
Responsible party
Jorg G. Albert (Prof. Dr. med., Robert Bosch Medical Center) — Principal investigator
First posted
May 27, 2021
Start date
Mar 7, 2021
Primary completion
Mar 31, 2022 (estimated)
Completion
Mar 31, 2023 (estimated)
Last update
May 27, 2021

Study contacts

Joerg G. Albert
Contact
joerg.albert@rbk.de
004971181013406
Bea Poppel
Contact
bea.poppel@rbk.de
004971181015453
Joerg G. Albert
study director · Robert Bosch Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion